Early insulin use in type 2 diabetes: what are the cons?
Chiasson
Jean-Louis
JL
Research Centre, Centre Hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montreal, Canada. Jean-Louis Chiasson, jean.louis.chiasson@umontreal.ca
D015179:Colorectal Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000453:epidemiology; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use*; D008833:Microcirculation / Q000187:drug effects; D012306:Risk; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds